MA37645A3 - Formulations stabilisées contenant des anticorps anti-dll4 - Google Patents

Formulations stabilisées contenant des anticorps anti-dll4

Info

Publication number
MA37645A3
MA37645A3 MA37645A MA37645A MA37645A3 MA 37645 A3 MA37645 A3 MA 37645A3 MA 37645 A MA37645 A MA 37645A MA 37645 A MA37645 A MA 37645A MA 37645 A3 MA37645 A3 MA 37645A3
Authority
MA
Morocco
Prior art keywords
formulations containing
containing anti
antibody
dll4 antibodies
stabilized formulations
Prior art date
Application number
MA37645A
Other languages
English (en)
Other versions
MA37645B1 (fr
MA37645A2 (fr
Inventor
Scott Walsh
Daniel Dix
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37645(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA37645A2 publication Critical patent/MA37645A2/fr
Publication of MA37645A3 publication Critical patent/MA37645A3/fr
Publication of MA37645B1 publication Critical patent/MA37645B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques comprenant un anticorps qui se lie spécifiquement à un ligand humain delta-like 4 (dll4). Lesdites formulations peuvent contenir, outre un anticorps anti-dll4, un tampon de phosphate, un co-solvant organique, un disaccharide, et un sel. Les formulations pharmaceutiques selon la présente invention présentent un degré substantiel de stabilité d'anticorps après stockage pendant plusieurs mois et après avoir été soumises à une contrainte thermique et à d'autres contraintes physiques.
MA37645A 2012-05-31 2013-05-31 Formulations stabilisées contenant des anticorps anti-dll4 MA37645B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31
PCT/US2013/043516 WO2013181486A1 (fr) 2012-05-31 2013-05-31 Formulations stabilisées contenant des anticorps anti-dll4

Publications (3)

Publication Number Publication Date
MA37645A2 MA37645A2 (fr) 2016-08-31
MA37645A3 true MA37645A3 (fr) 2017-07-31
MA37645B1 MA37645B1 (fr) 2018-10-31

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37645A MA37645B1 (fr) 2012-05-31 2013-05-31 Formulations stabilisées contenant des anticorps anti-dll4

Country Status (30)

Country Link
US (1) US9675692B2 (fr)
EP (1) EP2854849B1 (fr)
JP (1) JP6144758B2 (fr)
KR (1) KR20150033615A (fr)
CN (1) CN104349791A (fr)
AR (1) AR092325A1 (fr)
AU (1) AU2013267301B2 (fr)
BR (1) BR112014028997A2 (fr)
CA (1) CA2872275C (fr)
CL (1) CL2014003237A1 (fr)
CO (1) CO7151478A2 (fr)
DK (1) DK2854849T3 (fr)
EA (1) EA029779B1 (fr)
ES (1) ES2668900T3 (fr)
HK (1) HK1207305A1 (fr)
IL (1) IL235468A0 (fr)
LT (1) LT2854849T (fr)
MA (1) MA37645B1 (fr)
MX (1) MX357146B (fr)
NO (1) NO2887943T3 (fr)
NZ (1) NZ702288A (fr)
PH (1) PH12014502429B1 (fr)
PL (1) PL2854849T3 (fr)
PT (1) PT2854849T (fr)
SG (1) SG11201407171XA (fr)
SI (1) SI2854849T1 (fr)
SM (1) SMT201800216T1 (fr)
TW (1) TWI609696B (fr)
UY (1) UY34842A (fr)
WO (1) WO2013181486A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3485908B1 (fr) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
EP3212233B1 (fr) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Thérapie combinée pour le traitement d'une maladie
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
CA3097058A1 (fr) * 2018-04-16 2019-10-24 Merck Patent Gmbh Additifs pour formulations proteiques en vue d'ameliorer la stabilite thermique
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CA3185091A1 (fr) * 2020-07-08 2022-01-13 Yuan Cheng Formulations stabilisees contenant des anticorps anti-ctla-4

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE230277T1 (de) 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
WO2005072772A1 (fr) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Compositions pharmaceutiques
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA3142945A1 (fr) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Formulations a tampon d'histidine d'antagoniste du vegf
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
CA2654510C (fr) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Formulations antagonistes du vegf appropriees a une administration intravitreenne
WO2008049897A1 (fr) 2006-10-27 2008-05-02 Ablynx N.V. Administration intranasale de polypeptides et de protéines
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
EP3485908B1 (fr) * 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs
PL3721904T3 (pl) 2009-11-20 2022-01-31 Biocon Limited Formulacje przeciwciała t1h
WO2011109298A2 (fr) * 2010-03-02 2011-09-09 Abbott Laboratories Protéines thérapeutiques de liaison à dll4
MX366337B (es) * 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).

Also Published As

Publication number Publication date
ES2668900T3 (es) 2018-05-23
MX357146B (es) 2018-06-28
EP2854849A1 (fr) 2015-04-08
NZ702288A (en) 2016-12-23
PT2854849T (pt) 2018-05-09
PL2854849T3 (pl) 2018-07-31
CN104349791A (zh) 2015-02-11
TW201400130A (zh) 2014-01-01
JP6144758B2 (ja) 2017-06-07
AU2013267301B2 (en) 2018-02-08
TWI609696B (zh) 2018-01-01
EA201492186A1 (ru) 2015-08-31
KR20150033615A (ko) 2015-04-01
CL2014003237A1 (es) 2015-07-10
MX2014014363A (es) 2015-02-05
EA029779B1 (ru) 2018-05-31
SMT201800216T1 (it) 2018-05-02
PH12014502429A1 (en) 2015-01-12
PH12014502429B1 (en) 2015-01-12
US20130323260A1 (en) 2013-12-05
AU2013267301A1 (en) 2014-12-18
JP2015520173A (ja) 2015-07-16
UY34842A (es) 2013-12-31
SG11201407171XA (en) 2014-11-27
BR112014028997A2 (pt) 2017-07-25
AR092325A1 (es) 2015-04-15
WO2013181486A1 (fr) 2013-12-05
US9675692B2 (en) 2017-06-13
LT2854849T (lt) 2018-05-10
HK1207305A1 (en) 2016-01-29
SI2854849T1 (en) 2018-05-31
DK2854849T3 (en) 2018-04-30
CO7151478A2 (es) 2014-12-29
CA2872275A1 (fr) 2013-12-05
EP2854849B1 (fr) 2018-02-28
NO2887943T3 (fr) 2018-05-05
CA2872275C (fr) 2021-05-18
MA37645B1 (fr) 2018-10-31
MA37645A2 (fr) 2016-08-31
IL235468A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
MA37645B1 (fr) Formulations stabilisées contenant des anticorps anti-dll4
MA35904B1 (fr) Formulations stabilisées contenant des anticorps anti-ang2
Yewdell et al. Original antigenic sin: how original? How sinful?
MA33993B1 (fr) Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r)
MA35355B1 (fr) Formulations stabilisées contenant des anticorps anti-pcsk9
AR130402A2 (es) Formulaciones de anticuerpos anti-pdl1
EP3941945A4 (fr) Anticorps dirigés contre l'antigène trophoblaste 2 de surface cellulaire (trop2) et conjugués anticorps-médicament les comprenant
SG11201907321TA (en) Anti-gprc5d antibody and molecule comprising the antibody
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
JO3449B1 (ar) صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
JP2007520566A5 (fr)
PH12013500672A1 (en) Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies
MA62173B1 (fr) Formulations d'anticorps anti-rankl humains et leurs procédés d'utilisation
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
FR18C1032I2 (fr) Anticorps anti-fgf23 et composition pharmaceutique le comprenant
EP2471814A4 (fr) Anticorps monoclonal anti-vegf et composition pharmaceutique comprenant ledit anticorps
IL194550A (en) Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
IL214779A (en) Isolated monoclonal antibody or epitope-binding antibody on cadm1, methods of preparation and use for drug preparation
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
EP3983446A4 (fr) Anticorps anti-epcam conditionnellement actifs, fragments d'anticorps, leurs immunoconjugués et utilisations associées
PH12021552092A1 (en) Stabilized formulations containing anti-il-33 antibodies
Corral et al. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis
EA201070826A1 (ru) Антитела против pcrv
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
TR201007250A2 (tr) Selobioz içeren formülasyon.